Pacira Confirms Board Defense and Highlights 6.2% Exparel Growth with $150M Buybacks
Pacira said DOMA nominated three director candidates but no shareholder action is required ahead of its 2026 Annual Meeting. In 2025 the company treated 2.5 million patients, grew Exparel volume by 6.2%, achieved 79% GAAP gross margin, secured 21 Orange-Book patents and repurchased $150 million in shares.
1. Response to Activist Nomination
Pacira responded to DOMA’s nomination of three director candidates, stating no shareholder action is required and reaffirming the board’s commitment to its 5x30 strategy and shareholder interests ahead of the 2026 Annual Meeting.
2. Progress on 5x30 Strategy
The company reported treating 2.5 million patients in 2025 and grew Exparel volume by 6.2% year over year, reinforcing its trajectory toward serving 3 million patients annually and achieving double-digit compounded topline growth by 2030.
3. Financial and Shareholder Returns
Pacira achieved record 79% GAAP and 81% non-GAAP gross margins in 2025, executed $150 million in share repurchases reducing outstanding shares from 47 to 41 million, and emphasized disciplined capital allocation.
4. Intellectual Property and Pipeline Advances
The company secured a favorable volume-limited patent settlement, expanded its Orange-Book listed patents to 21, established commercial collaborations with J&J MedTech and LG Chem, and outlined key 2026 milestones for Zilretta, iovera and its PCRX-201 Phase 2 trial.